A rating of 80 puts Crispr Therapeutics AG (CRSP) near the top of the Biotechnology industry according to InvestorsObserver. Crispr Therapeutics AG's score of 80 means it scores higher than 80% of stocks in the industry. Crispr Therapeutics AG also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 36 out of the 148 industries.
What do These Ratings Mean?
Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.
This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.
What's Happening With Crispr Therapeutics AG Stock Today?
Crispr Therapeutics AG (CRSP) stock is higher by 4.47% while the S&P 500 has fallen -0.3% as of 1:19 PM on Monday, Dec 7. CRSP is higher by $6.60 from the previous closing price of $147.54 on volume of 2,324,656 shares. Over the past year the S&P 500 has gained 17.61% while CRSP is higher by 128.52%. CRSP lost -$3.25 per share the over the last 12 months.